These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21691126)

  • 21. DDAVP (1-desamino-8-D-arginine vasopressin): an antagonist of the pressor action of endogenous vasopressin?
    Derkx FH; Man in 't Veld AJ; Jones R; Reid JL; Schalekamp MA
    J Hypertens Suppl; 1983 Dec; 1(2):58-61. PubMed ID: 6400119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal response to prostaglandin E1 infusion in polycystic kidney disease versus non-polycystic renal disease.
    Uemasu J; Munemura C; Fujihara M; Kawasaki H
    Clin Nephrol; 1995 Oct; 44(4):225-30. PubMed ID: 8575121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Up-regulation of renal adenylate cyclase-coupled vasopressin receptors after chronic administration of vasopressin antagonists to rats.
    Caltabiano S; Kinter LB
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1046-54. PubMed ID: 1832462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
    Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
    Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Ulusoy S; Ozkan G; Orem C; Kaynar K; Koşucu P; Kiriş A
    Ren Fail; 2010; 32(8):913-7. PubMed ID: 20722556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments.
    Braun WE
    Cleve Clin J Med; 2009 Feb; 76(2):97-104. PubMed ID: 19188475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinases synthesized in autosomal dominant polycystic kidney disease play a role in development of a concurrent abdominal aortic aneurysm.
    Takagi H; Umemoto T
    Med Hypotheses; 2005; 64(4):778-81. PubMed ID: 15694696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State-dependent plasticity in vasopressin neurones: dehydration-induced changes in activity patterning.
    Scott V; Brown CH
    J Neuroendocrinol; 2010 May; 22(5):343-54. PubMed ID: 20088912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical practice. Autosomal dominant polycystic kidney disease.
    Grantham JJ
    N Engl J Med; 2008 Oct; 359(14):1477-85. PubMed ID: 18832246
    [No Abstract]   [Full Text] [Related]  

  • 30. [Polycystic kidney disease].
    Higashihara E
    Nihon Jinzo Gakkai Shi; 2007; Suppl 50th Ann():83-90. PubMed ID: 17899832
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanisms of progression in autosomal dominant polycystic kidney disease.
    Grantham JJ
    Kidney Int Suppl; 1997 Dec; 63():S93-7. PubMed ID: 9407432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion.
    Padfield PL; Brown JJ; Lever AF; Morton JJ; Robertson JI
    N Engl J Med; 1981 Apr; 304(18):1067-70. PubMed ID: 7207565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.
    Rule AD; Torres VE; Chapman AB; Grantham JJ; Guay-Woodford LM; Bae KT; Klahr S; Bennett WM; Meyers CM; Thompson PA; Miller JP;
    J Am Soc Nephrol; 2006 Mar; 17(3):854-62. PubMed ID: 16452494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laparoscopic bilateral hand assisted nephrectomy for autosomal dominant polycystic kidney disease: initial experience.
    Rehman J; Landman J; Andreoni C; McDougall EM; Clayman RV
    J Urol; 2001 Jul; 166(1):42-7. PubMed ID: 11435819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review.
    den Ouden DT; Meinders AE
    Neth J Med; 2005 Jan; 63(1):4-13. PubMed ID: 15719846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The management in chronic kidney disease (CKD)].
    Busuioc M; Gusbeth-Tatomir P; Covic A
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(4):896-901. PubMed ID: 20209759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease.
    Ahmed ER; Tashkandi MA; Nahrir S; Maulana A
    Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):511-5. PubMed ID: 17186685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Myth of Water and Salt: From Aquaretics to Tenapanor.
    Visconti L; Cernaro V; Calimeri S; Lacquaniti A; De Gregorio F; Ricciardi CA; Lacava V; Santoro D; Buemi M
    J Ren Nutr; 2018 Mar; 28(2):73-82. PubMed ID: 29146141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasopressin: a novel target for the prevention and retardation of kidney disease?
    Bankir L; Bouby N; Ritz E
    Nat Rev Nephrol; 2013 Apr; 9(4):223-39. PubMed ID: 23438973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.